

Vyvanse[®] (lisdexamfetamine) – First-time generic

- On August 25, 2023, Norwich/[Alvogen](#), Hikma, Sun, Solco/Prinston, [Amneal](#) and Viartis launched AB-rated generic versions of Takeda's [Vyvanse \(lisdexamfetamine\)](#) extended-release capsules and Sun launched an [AB-rated](#) generic version of Vyvanse chewable tablets.
 - In addition, the [FDA approved](#) several other manufacturers of generic Vyvanse. Launch is pending for these additional manufacturers.
- Vyvanse is approved for the treatment of attention deficit hyperactivity disorder in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults.
- Vyvanse carries a boxed warning for abuse and dependence.